Natera (NASDAQ:NTRA) Director Rowan Chapman Sells 122 Shares

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 122 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $191.38, for a total value of $23,348.36. Following the sale, the director owned 5,752 shares of the company’s stock, valued at approximately $1,100,817.76. This represents a 2.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Natera Stock Up 0.4%

Shares of NASDAQ:NTRA opened at $198.38 on Wednesday. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The stock’s 50 day moving average is $217.92 and its 200-day moving average is $207.15. The firm has a market capitalization of $28.12 billion, a price-to-earnings ratio of -129.66 and a beta of 1.65.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. The business had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same quarter last year, the firm posted ($0.41) EPS. Equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of analyst reports. BTIG Research upped their target price on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Morgan Stanley dropped their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. UBS Group upped their price target on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. JPMorgan Chase & Co. raised their price objective on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average target price of $253.47.

Hedge Funds Weigh In On Natera

Several institutional investors have recently modified their holdings of NTRA. Mozayyx Management LLC purchased a new position in Natera in the fourth quarter worth $309,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Natera in the 4th quarter worth about $175,000. Reflection Asset Management bought a new position in Natera during the fourth quarter valued at about $29,000. Tobam grew its position in Natera by 24,935.0% during the fourth quarter. Tobam now owns 5,007 shares of the medical research company’s stock valued at $1,147,000 after buying an additional 4,987 shares during the period. Finally, Groupama Asset Managment increased its holdings in Natera by 19.5% during the fourth quarter. Groupama Asset Managment now owns 92,256 shares of the medical research company’s stock worth $21,135,000 after buying an additional 15,072 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.